Russia's Sputnik V 91.6% effective with good safety profile in trials

In the interim efficacy analysis, data from 19,866 volunteers were included

The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) said on Tuesday that interim results published in The Lancet, a peer-reviewed medical journal, have confirmed the efficacy of the Sputnik V vaccine at 91.6 per cent in phase 3 trial. RDIF's India partner, Dr Reddy's Laboratories, which is also conducting the clinical trials here, has said that it would apply for emergency approval in March and that it aims to launch the vaccine in the same month.
 

Based on the human adenoviral (flu virus) vector platform, Sputnik V showed higher efficacy in the